<DOC>
	<DOCNO>NCT00995332</DOCNO>
	<brief_summary>Hypothesis : Combined treatment valproic acid ATRA use achieve disease stabilization subset patient acute myelogenous leukemia ( AML ) , effect improve without serious toxicity add low-dose cytarabine treatment . Adult patient &gt; 18 year age include : Elderly patient achieve standard chemotherapy , patient relapse resistant AML . Treatment : Combined therapy : Valproic acid , continuous therapy disease progression ATRA , oral therapy 14 day every three month Low-dose cytarabine 10 mg/m2 10 injection week 2 3 , repeat every 3 month .</brief_summary>
	<brief_title>Disease Stabilization AML Treatment With ATRA , Valproic Acid Low-dose Cytarabine</brief_title>
	<detailed_description>Patients include : 1 . Elderly patient ( &gt; 60 year age ) patient unfit conventional intensive chemotherapy newly diagnose acute myelogenous leukemia ( AML ) . 2 . Adult patient age ( &gt; 18 year age ) relapse resistant AML receive conventional therapy . Treatment : Valproic acid start day 1 continuous therapy disease progression . ATRA administer day 8 orally 22.5 mg/m2 twice daily 14 day , repeat every third month . Low-dose cytarabine 10 mg/m2 day 14 continue daily injection 10 day , repeat every third month . Supportive therapy give accord hospital general guideline . Followup : The first 2 day treatment hospital , later regular out-patient treatment . Controls include clinical examination , peripheral blood parameter ( include serum valproic acid level ) , bone marrow sample .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Recently diagnose AML patient unfit intensive chemotherapy Patients relapse refractory AML No inform consent Intolerance study drug Serious liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>all-trans retinoic acid</keyword>
	<keyword>valproic acid</keyword>
	<keyword>cytarabine</keyword>
	<keyword>Disease stabilization</keyword>
	<keyword>survival</keyword>
	<keyword>toxicity</keyword>
</DOC>